Insulet Corporation (PODD) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus sits below the midpoint of Q2 guidance on revenue, and the biggest swing factor is whether U.S. New Customer Starts (NCS) rebounded sequentially after the deductible-reset trough in Q1 and whether the May 26 medical device correction created any measurable demand disruption.

Heading into Q2 2026, the bar looks achievable: consensus total revenue of ~$787M sits at the low end of management's guided range of 20–22% growth, implying the Street has not fully credited the sequential NCS recovery management flagged as already underway in April. Management's tone on the Q1 call was notably confident — CEO Ashley McEvoy stated she is "absolutely more confident now in Insulet's potential than a year ago" — and the company raised full-year Omnipod revenue growth guidance to 22–24% (from 20–22%) after just one quarter. Estimate revisions have been modestly positive since the Q1 print, with FY2026 consensus revenue edging up to ~$3.325B from ~$3.329B at the post-Q1 baseline, broadly in line with the raised guidance. The stock has recovered from its May correction-driven lows (up ~+10% since the Q1 print vs. IHI +8.9% and SPY +5.1%), suggesting the market has largely absorbed the quality-control overhang, though the stock is not pricing in a blowout. The key wildcard is the second medical device correction (announced May 26) — management asserted at the ADA investor event in June that physician and patient feedback has been "very understanding" and that sales rep distraction faded after the initial days, but any evidence of NCS disruption in the Q2 print would be a meaningful negative surprise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus revenue of ~$787M sits at the low end of the guided 20–22% growth range, making the bar achievable. U.S. NCS is the bigger swing factor — a sequential recovery from Q1's deductible-reset trough is expected but not fully quantified by the Street, and any shortfall would pressure the stock disproportionately.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 guidance midpoints derived from Q1 2026 earnings call (May 6, 2026): total revenue growth 20–22%, Omnipod WW growth 21–23%, U.S. Omnipod growth 18–20%, International Omnipod growth 28–30%. Consensus vs. guidance delta calculated vs. guidance midpoint.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: Total Revenue & Adj. Operating EPS

Pattern: PODD has beaten consensus on both revenue and adjusted EPS in each of the last four reported quarters, with revenue beats averaging ~4% and EPS beats averaging ~14%. The consistent beat cadence reflects management's conservative guidance philosophy and strong operating leverage. The bar for Q2 2026 appears similarly achievable.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised at Q1 2026 earnings (May 6) and has not been formally revised since; management tone at the ADA investor event (June 8) was constructive, with no demand disruption from the second medical device correction and strong physician engagement from the expanded sales force.

Source: Q1 2026 Earnings Call transcript (May 6, 2026); Visible Alpha Consensus and Actuals Data. No post-earnings guidance revisions were filed via 8-K or pre-announcement. ADA investor event (June 8, 2026) provided qualitative commentary but no formal guidance update.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable-to-slightly-higher since the Q1 print, tracking the raised guidance. The gap between consensus and the guidance midpoint is narrow, suggesting limited cushion if execution disappoints but also a low bar for a beat.

Estimates have been essentially flat since the Q1 print, with revisions of less than −0.2% across all key metrics — the Street has anchored to the raised guidance without adding further cushion. This means consensus is a low bar relative to guidance midpoints, but there is no meaningful estimate drift to suggest the market is pricing in an upside surprise.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of approximately May 13, 2026 (5 trading days post Q1 earnings on May 6, 2026).

5. Stock Performance

Key Takeaway: PODD has outperformed both the medical device ETF (IHI) and the S&P 500 since the Q1 earnings print, driven by the strong beat-and-raise and recovery from the May 26 correction-driven selloff; the stock’s +10.3% gain vs. IHI +8.9% and SPY +5.1% suggests sentiment has improved but the stock is not pricing in a blowout.

PODD vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 6, 2026). Source: Stock Price Data.

• May 6 (Day 0): Q1 2026 earnings beat-and-raise. PODD surged from ~$120 pre-market close to $151.28 on the day. Stock recovered sharply from correction-depressed levels.
• May 13–15: Stock pulled back to ~$147–$149 range as the market digested the second medical device correction (announced May 26) concerns and broader sector rotation.
• May 26–27: Second voluntary medical device correction announced (cannula tears in specific Omnipod 5/DASH/Eros pod lots). Stock declined to ~$146–$142 range, underperforming IHI.
• June 3–8: Omnipod 5 algorithm enhancement and Libre 3 Plus integration launched (June 3). ADA Scientific Sessions (June 5–8) with STRIVE data for Omnipod 6 and EVOLUTION 3 FCL data presented. Stock recovered to ~$151–$159 range.
• June 22: Stock touched a post-earnings low of ~$138.97, likely reflecting broader sector weakness and lingering correction overhang.
• Late June – July: Steady recovery driven by improving sentiment on quality-control narrative and pipeline catalysts. Stock climbed from ~$138 to ~$170 by late July.
• August 4 (latest): PODD at $166.82, up +10.3% since Q1 earnings vs. IHI +8.9% and SPY +5.1%.

Sector ETF: IHI (iShares U.S. Medical Devices ETF) — appropriate for PODD’s medical device sub-sector. Source: Stock Price Data.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Both DXCM (reported July 30) and ABT (reported July 16) delivered constructive Q2 2026 commentary on the diabetes device market — strong new patient starts, expanding Type 2 access, and bullish long-term market views — all of which are positive read-throughs for PODD’s Q2 print and the durability of its growth algorithm.

Dexcom (DXCM) — Q2 2026 Earnings (Reported July 30, 2026)

Relevance: DXCM is PODD’s primary CGM integration partner (Dexcom G6/G7 powers Omnipod 5 in the U.S.) and competes in the broader diabetes device ecosystem. DXCM’s new patient start trends and market commentary are the most direct read-through for PODD’s NCS trajectory.

• Strong new patient starts: DXCM reported global new customer starts in Q2 2026 "remained in line with our previous record from last quarter, including a sequential uptick in new customer starts in the US." Step-up was broad-based across Type 1, Type 2 intensive basal, and Type 2 non-insulin segments. Read-through: Positive for PODD U.S. NCS recovery — if DXCM saw a sequential uptick in U.S. new starts, the same underlying patient flow should benefit PODD’s NCS, which management guided to recover from Q1’s deductible-reset trough.
• Type 2 market expansion: DXCM highlighted ~9 million Americans with CGM coverage who are not yet using it, and noted coverage for all people with diabetes across the four largest commercial PBMs as of summer 2026, representing 7M+ Type 2 non-insulin patients. CMS decision on non-insulin coverage expected before year-end, taking effect mid-2027. Read-through: Expanding CGM access directly expands PODD’s addressable market for Omnipod 5 and the future Fully Closed Loop system. Broader Type 2 coverage is a structural tailwind for PODD’s Type 2 NCS growth.
• Connect trial data: DXCM’s randomized control trial for Type 2 non-insulin patients showed 1.6% A1C improvement and 5+ more hours/day in normal glucose range vs. control, with 97% median CGM usage. Submitted to CMS. Read-through: Strong clinical evidence for CGM in Type 2 supports the broader AID adoption narrative that underpins PODD’s Type 2 growth thesis.
• Revenue beat and guidance raise: DXCM reported Q2 worldwide revenue of $1.31B (+13% YoY, +12% organic) and raised full-year guidance to $5.18–$5.25B (11–13% growth), also raising non-GAAP gross margin to ~64% and operating margin to 23.5–24%. Read-through: Positive sector sentiment heading into PODD’s print; demonstrates the diabetes device market is executing well in Q2 2026.
• G7 15-day conversion: DXCM on track to convert ~50% of U.S. customer base to G7 15-day by year-end; G7 NPS has increased in each of the last three quarters. Read-through: Improved CGM experience supports Omnipod 5 user satisfaction and retention, as PODD’s Libre 3 Plus integration (launched June 3) similarly expands sensor choice.

Abbott Laboratories (ABT) — Q2 2026 Earnings (Reported July 16, 2026)

Relevance: Abbott’s FreeStyle Libre is PODD’s newest CGM integration partner (Libre 3 Plus integration launched June 3, 2026, targeting ~450,000 current Libre 3 Plus users). ABT’s CGM market commentary and Type 2 access narrative are directly relevant to PODD’s international growth and U.S. Type 2 expansion.

• CGM market remains large and underpenetrated: ABT reported CGM sales exceeding $2B in Q2 (+9.5% growth) and remains "very bullish" on the market, noting only 15M of an estimated 75–80M potential global CGM users are currently on the technology. Read-through: Confirms the long-term CGM market opportunity that underpins PODD’s international growth runway; Libre 3 Plus integration opens PODD to a new pool of existing Libre users.
• Reimbursement expansion is the key growth catalyst: ABT noted that reimbursement expansion "dramatically accelerates" growth rates, and is in active discussions with ~12 countries on new or expanded coverage. France, Japan, and Canada have broadly adopted basal coverage; discussions ongoing with 7 more significant markets. Read-through: International reimbursement expansion is a direct driver of PODD’s international NCS growth. PODD’s guidance for 26–28% international Omnipod growth in FY2026 is supported by this macro tailwind.
• U.S. Type 2 Medicare opportunity: ABT highlighted the U.S. Type 2 market as a "huge opportunity" that could unlock ~10M Medicare beneficiaries and accelerate commercial insurance coverage, potentially becoming a "multibillion dollar opportunity" that "could happen in the fall." Read-through: A Medicare Type 2 CGM coverage expansion would be a significant catalyst for PODD’s Type 2 NCS growth, as broader CGM access drives AID adoption. This is a potential positive wildcard for PODD’s 2H 2026 and 2027 outlook.
• GLP-1 coexistence confirmed: ABT’s data from the Epic Cosmos database shows 41% of Type 2 patients are on GLP-1s, yet insulin use has remained constant at 26% since 2007. ABT’s own research shows 43% of GLP-1-only patients have A1C >7%, and 67% of GLP-1 + MDI patients are not at target. Read-through: Directly corroborates PODD management’s assertion that GLP-1s are not reducing the insulin-dependent Type 2 market. Removes a key bear concern heading into the print.
• Manufacturing investment signals confidence: ABT is planning a fifth manufacturing facility (~$1B investment) as it expects to approach capacity at its fourth facility within a couple of years. Read-through: Signals sustained CGM demand growth, which is a prerequisite for PODD’s AID growth thesis. Consistent with PODD’s own Costa Rica facility announcement for 2029.

Source: DXCM Q2 2026 Earnings Call transcript (July 30, 2026); ABT Q2 2026 Earnings Call transcript (July 16, 2026).

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the May 26 second medical device correction, which created a sharp stock selloff but appears to have had limited commercial impact based on ADA conference feedback; the June 3 algorithm/Libre 3 Plus launch and ADA pipeline data are the key positive catalysts heading into the print.

• May 26, 2026 — Second Voluntary Medical Device Correction (MDC): PODD announced a second voluntary MDC covering specific lots of Omnipod 5, DASH, and Eros pods in the U.S. and international markets due to cannula tears above the skin causing potential insulin under-delivery. Management stated all affected product predates enhanced quality controls from the March MDC, and a comprehensive look-back found no additional issues. 2026 guidance was not changed. Implication: Key risk to watch — any evidence of NCS disruption in Q2 would be a significant negative surprise. ADA conference feedback (June 8) suggested minimal commercial impact.
• June 3, 2026 — Omnipod 5 Algorithm Enhancement & Libre 3 Plus Integration Launch: PODD launched the most significant algorithm update since Omnipod 5’s 2022 debut, featuring a new lower target glucose of 100 mg/dL and improved alarm handling for more time in automated mode. Simultaneously launched integration with Abbott’s FreeStyle Libre 3 Plus sensor, targeting ~450,000 current Libre 3 Plus users. Also launched Omnipod Discover data insights platform. Implication: Positive for Q2 NCS and retention; expands addressable market and addresses the algorithm competitiveness concern that has been a bear thesis.
• June 5–8, 2026 — ADA 86th Scientific Sessions (New Orleans): PODD presented STRIVE pivotal trial data for Omnipod 6 (4% TIR improvement to 77%, 7% time-in-tight-range improvement, 40% bolus reduction in bolus-optional phase) and EVOLUTION 3 pre-pivotal data for the Fully Closed Loop Type 2 system (TIR improved from 51% baseline to 66% by week 6, no bolusing required, no settings to enter). Implication: Strong clinical data supports the Omnipod 6 (2027 launch) and FCL Type 2 (2028 launch) pipeline narrative; reduces algorithm competitiveness concerns.
• June 8, 2026 — ADA Cardiometabolic Health Portfolio Investor Event: Management confirmed sales force expanded ~25%, physician and patient feedback on the MDC has been "very understanding," and there has been "no discussion" of the recall at the ADA conference after the initial days. Primary care provider interest in Omnipod described as strong. Implication: Reduces MDC commercial impact risk; sales force expansion supports NCS recovery.
• June 25, 2026 — Board Appointment (Jonathan Mazelsky): PODD appointed former IDEXX Laboratories CEO Jonathan (Jay) Mazelsky to its Board of Directors, effective July 1, 2026. Under Mazelsky’s leadership at IDEXX, revenues and stock price nearly doubled. Implication: Adds experienced medtech/diagnostics leadership; signals confidence in long-term growth trajectory.
• July 1, 2026 — Q2 2026 Earnings Date Announcement: PODD confirmed Q2 2026 results will be reported August 5, 2026, pre-market, with a conference call at 8:00 a.m. ET. No pre-announcement or guidance update was included.
• Ongoing — EVOLVE Pivotal Study Enrollment: First participant enrolled in May 2026 in the EVOLVE pivotal study for the Fully Closed Loop Type 2 system. Enrollment expected to continue through most of 2026 (~300 patients, 13-week trial). FDA filing targeted for 2027, commercial launch in 2028. Implication: Execution on the most important long-term growth catalyst; on track per management timeline.
• Ongoing — GLP-1 Coexistence Data: Epic Cosmos database data (through end of 2025) shows 41% of Type 2 patients are on GLP-1s, yet insulin use has remained constant at 26% since 2007. PODD management and ABT both cited this data at ADA. Implication: Removes a key bear concern; GLP-1 adoption is not cannibalizing the insulin-dependent Type 2 market.

8. Insider Transaction Activity

Key Takeaway: No open-market discretionary buys or sells by executives since Q1 earnings; activity is limited to routine director equity grants and tax-withholding share forfeitures. Two directors made small open-market purchases in early June, which is a mild positive signal but not a strong conviction buy.

Notable: Two directors (Stonesifer and Weatherman) made small open-market purchases on June 3, 2026 — the same day as the Omnipod 5 algorithm and Libre 3 Plus integration launch — at prices in the ~$143 range, which is below the current stock price. This is a mild positive signal but not a strong conviction buy given the small size. No executive (C-suite) open-market purchases or discretionary sales were recorded in the period. CEO McEvoy’s May 13 transaction was a routine tax-withholding forfeiture on vesting, not a discretionary sale. The absence of executive selling is a neutral-to-positive signal.

Source: Insider Transaction Data (SEC Form 4 filings, May 6 – August 4, 2026). Open-market buys (code P) and sells (code S) only; award grants (code A) and tax withholdings (code F) included for completeness.